Metformin safety and neuroprotection in older adults with MS: 9-month RCT.
A randomized, placebo-controlled pilot study examined metformin extended-release (1500 mg/day) as monotherapy or add-on treatment in older people with multiple sclerosis. The study assessed safety, tolerability, and neuroprotective effects measured by brain MRI over 9 months. No results or findings are reported in this abstract.
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Nov 21, 2025 · Discovered: Sep 15, 2026 · Assessed: — · Research update
What it does not prove
- Limitations have not yet been verified. Read the primary source.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- 9 months
- Population
- Older people with multiple sclerosis (MS)
- Primary outcome
- Safety and tolerability of metformin extended release (1500 mg/day) as a single therapy or as an add-on therapy in older people with MS compared to placebo
- Effect size
- —
- Significance
- Not reported
- Journal
- State University of New York at Buffalo
- Published
- Nov 21, 2025
Sources
Primary source
- State University of New York at Buffalo ↗Clinical trial
Source versions
Assessment history
9/23/2026 · SUPERSEDED: Source updated; assessment withdrawn pending review.
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
No comments yet
Be the first to weigh in on this evidence.